Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
The gradual loss of DNA from the ends of telomeres has been implicated in the control of cellular proliferative potential. Telomerase is an enzyme that restores telomeric DNA sequences, and expression of its activity was thought to be essential for the immortalization of human cells, both in vitro and in tumor progression in vivo. Telomerase activity has been detected in 50-100% of tumors of different types, but not in most normal adult somatic tissues. It has also been detected in about 70% of human cell lines immortalized in vitro and in all tumor-derived cell lines examined to date. It has previously been shown that in vitro immortalized telomerase-negative cell lines acquire very long and heterogeneous telomeres in association with immortalization presumably via one or more novel telomere-lengthening mechanisms that we refer to as ALT (alternative lengthening of telomeres). Here we report evidence for the presence of ALT in a subset of tumor-derived cell lines and tumors. The maintenance of telomeres by a mechanism other than telomerase, even in a minority of cancers, has major implications for therapeutic uses of telomerase inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a few rare tumors (29) and some experimentally immortalized cell lines (30) lack detectable telomerase activity.”
From Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death (1999) · cites this paper as [30]
In the citing paper
“Virally transformed human cells that eliminate p53 and/or pRB function can escape crisis at very low frequencies, and invariably adopt telomere-maintenance programs: 80-90% of human tumors possess some telomerase activity, while the remainder maintain telomeres via a recombination-mediated process termed ALT (for Alternative Lengthening of Telomeres)37-40.”
From Telomere dysfunction and tumour suppression: the senescence connection (2008) · cites this paper as [39]
In the citing paper
“A significant number of human tumours can also maintain telomeres by recombination-based ALT mechanisms in the absence of telomerase 72 .”
From The common biology of cancer and ageing (2007) · cites this paper as [72]
Citations
Cites
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091
Telomeres shorten during ageing of human fibroblasts
Harley, C. B., Futcher, A. B., & Greider, C. W. (1990) · Nature · doi:10.1038/345458a0 · Cited by 5,750
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Identification of a specific telomere terminal transferase activity in tetrahymena extracts
Greider, C. W., & Blackburn, E. H. (1985) · Cell · doi:10.1016/0092-8674(85)90170-9 · Cited by 3,400
Counter, C. M., Avilion, A. A., LeFeuvre, C. E., Stewart, N. G., Greider, C. W., Harley, C. B., & Bacchetti, S. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05245.x · Cited by 2,096
Telomere reduction in human colorectal carcinoma and with ageing
Hastie, N. D., Dempster, M., Dunlop, M. G., Thompson, A. M., Green, D. K., & Allshire, R. C. (1990) · Nature · doi:10.1038/346866a0 · Cited by 1,650
Telomere elongation in immortal human cells without detectable telomerase activity
Bryan, T. M., Englezou, A., Gupta, J., Bacchetti, S., & Reddel, R. R. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00098.x · Cited by 1,279
Self-citationTelomere loss: mitotic clock or genetic time bomb?
Harley, C. B. (1991) · Mutation Research/DNAging · doi:10.1016/0921-8734(91)90018-7 · Cited by 1,139
An alternative pathway for yeast telomere maintenance rescues est1− senescence
Lundblad, V., & Blackburn, E. H. (1993) · Cell · doi:10.1016/0092-8674(93)90234-h · Cited by 942
Telomerase activity in human ovarian carcinoma.
Counter, C. M., Hirte, H. W., Bacchetti, S., & Harley, C. B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.2900 · Cited by 677
Cited by
Items 401–500 of 1,000
Genetics of cellular senescence
Tominaga, K., Olgun, A., Smith, J. R., & Pereira‐Smith, O. M. (2002) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(02)00030-1 · Cited by 57
Association of p16INK4a and pRb inactivation with immortalization of human cells
Tsutsui, T., Kumakura, S.-I., Yamamoto, A., Kanai, H., Tamura, Y., Kato, T., Anpo, M., Tahara, H., & Barrett, J. C. (2002) · Carcinogenesis · doi:10.1093/carcin/23.12.2111 · Cited by 55
“Requirement of inactivation of p16INK4a and pRb functions accompanied by activation of telomere maintenance mechanisms, including telomerase or an alternative mechanism known as ALT (alternative lengthening of telomeres) ( 16 ), is also demonstrated in human fibroblast cell lines immortalized by introduction of HPV-16…”
BackgroundTelomerase Activity in Germ Cell Cancers and Mature Teratomas
Albanell, J., Bosl, G. J., Reuter, V. E., Engelhardt, M. M., Franco, S., Moore, M. A. S., & Dmitrovsky, E. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1321 · Cited by 61
Osteosarcoma in Pediatric and Adult Populations: Are Adults Just Big Kids?
Kim, C., Davis, L. E., Albert, C. M., Samuels, B. L., Roberts, J. L., & Wagner, M. J. (2023) · Cancers · doi:10.3390/cancers15205044 · Cited by 65
“The alternate mechanism of telomere maintenance (ALT), which is defined by heterogenous and elongated telomeres without telomerase activity, is one mechanism by which sarcoma cells avoid senescence [79,80].”
BackgroundIntratumoral diversity of telomere length in individual neuroblastoma tumors
Pezzolo, A., Pistorio, A., Gambini, C., Haupt, R., Ferraro, M., Erminio, G., Bernardi, B. D., Garaventa, A., & Pistoia, V. (2014) · Oncotarget · doi:10.18632/oncotarget.2115 · Cited by 55
“Telomere elongation is operated by telomerase and ALT mechanism, that is based on recombination of telomeric sequences and might cause heterogeneous TL in single cancer cells [10-12].”
The role of post-translational modifications in fine-tuning BLM helicase function during DNA repair
Böhm, S., & Bernstein, K. A. (2014) · DNA repair · doi:10.1016/j.dnarep.2014.07.007 · Cited by 58
“%) contain telomeric DNA that resides within PML-NBs forming ALTassociated PML bodies (APBs) ([48], and reviewed in [84]).”
BackgroundInfluentialKIM, J. H., KIM, J. H., Lee, G. E., KIM, S. W., & CHUNG, I. K. (2003) · Biochemical Journal · doi:10.1042/bj20030363 · Cited by 55
Cellular longevity: role of apoptosis and replicative senescence
Bree, R. T., Stenson-Cox, C., Grealy, M., Byrnes, L., Gorman, A. M., & Samali, A. (2002) · Biogerontology · doi:10.1023/a:1016299812327 · Cited by 62
“However, a number of tumors, tumor-derived cell lines and in vitro immortalised cell lines have been described that do not contain telomerase activity, yet their telomeres appear to be capable of lengthening (Bryan et al. 1995, 1997; Reddel et al. 1997).”
Yan, P., Coindre, J., Benhattar, J., Bosman, F. T., & Guillou, L. (1999) · PubMed · Cited by 58
Telomere dysfunction: multiple paths to the same end
Harrington, L. A., & Robinson, M. O. (2002) · Oncogene · doi:10.1038/sj.onc.1205084 · Cited by 66
“Immortalized cells are thought to avoid telomere dysfunction by either the activation of endogenous telomerase activity, or other rarer alternative means of telomere length maintenance (referred to as ALT) (Bryan et al., 1997; Dunham et al., 2000).”
BackgroundYan, P., Benhattar, J., Coindre, J., & Guillou, L. (2002) · International Journal of Cancer · doi:10.1002/ijc.10285 · Cited by 55
“reciprocal translocation t(12,16) (q13;p11) or, more rarely, a translocation t(12;22) (q13;q12), in addition to abnormalities involving the p53 (mutations of the p53 gene, overexpression of mdm2,.”
BackgroundFishman, D. A., & Bozorgi, K. (2002) · Springer eBooks · doi:10.1007/978-1-4757-3587-1_1 · Cited by 54
Gocha, A. R. S., Nuovo, G. J., Iwenofu, O. H., & Groden, J. L. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.10.001 · Cited by 60
Nucleostemin prevents telomere damage by promoting PML-IV recruitment to SUMOylated TRF1
Hsu, J. K., Lin, T., & Tsai, R. Y. L. (2012) · The Journal of Cell Biology · doi:10.1083/jcb.201109038 · Cited by 58
“Those telomerase-inactive cells are known as alternative lengthening of telomeres (ALT) cells and are thought to use the homologous recombination (HR) mechanism for telomere maintenance (Bryan et al., 1995, 1997; Shay and Bacchetti, 1997; Liu et al., 2007).”
BackgroundFarahzadi, R., Fathi, E., Mesbah‐Namin, S. A., & Zarghami, N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188052 · Cited by 53
RetractedTelomerase: Dr Jekyll or Mr Hyde?
Prescott, J. C., & Blackburn, E. H. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80055-0 · Cited by 59
Senescence: an antiviral defense that is tumor suppressive?
Reddel, R. R. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp274 · Cited by 50
Self-citationCaspase-Dependent Apoptosis Induced by Telomere Cleavage and TRF2 Loss
Multani, A. S., Özen, M., Narayad, S., Kumar, V., Chandra, J., McConkey, D. J., Newman, R. A., & Pathak, S. (2000) · Neoplasia · doi:10.1038/sj.neo.7900105 · Cited by 52
Jiang, W.-Q., Zhong, Z.-H., Nguyen, A., Henson, J. D., Toouli, C. D., Braithwaite, A. W., & Reddel, R. R. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200810084 · Cited by 49
“Telomerase is active in 85% of cancers (Shay and Bacchetti, 1997), and an ALT mechanism is active in many telomerase-negative tumors (Bryan et al., 1997; Henson et al., 2005).”
BackgroundSelf-citationLin, C., Chang, H.-H., Wu, K., Tseng, S., Lin, C., Lin, C., & Teng, S. (2005) · Eukaryotic Cell · doi:10.1128/ec.4.2.327-336.2005 · Cited by 57
Balk, B., Dees, M., Bender, K., & Luke, B. (2014) · RNA Biology · doi:10.4161/rna.27798 · Cited by 52
Saini, N., Srinivasan, R., Chawla, Y. K., Sharma, S., Chakraborti, A., & Rajwanshi, A. (2009) · Liver International · doi:10.1111/j.1478-3231.2009.02082.x · Cited by 51
“To date, clear evidence for ALT activity has only been found in some immortalized human cell lines and in telomerase-null mouse cell lines (40, 41).”
BackgroundMethionine restriction beyond life‐span extension
Ables, G. P., Hens, J. R., & Nichenametla, S. N. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13014 · Cited by 57
Telomeres and genomic evolution
Baird, D. M. (2018) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2016.0437 · Cited by 54
“Mutations leading to the upregulation of telomerase activity are required for malignant progression in at least 85% of tumours [5], with the remaining tumours adopting the alternative lengthening of telomeres phenotype [6].”
BackgroundWang, L., Xiao, H., Zhang, X., Wang, C., & Huang, H. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0061-9 · Cited by 57
“ATM: Ataxia telangiectasia-mutated gene; ATR: Ataxia telangiectasia and Rad3; ALT: Alternative lengthening of telomeres; ss DNA: Single-strand DNA; ds DNA: Double-strand DNA; TRF1: Telomeric repeat-binding factors 1; TRF2: Telomeric repeat-binding factors 2; TIN2: TRF1-interacting nuclear factor 2; Rap1: TRF2-interact…”
BackgroundInfluentialTelomere length maintenance in aging and carcinogenesis.
Aragona, M., Maisano, R., Panetta, S., Giudice, A., Morelli, M., Torre, I. L., & Torre, F. L. (2000) · International Journal of Oncology · doi:10.3892/ijo.17.5.981 · Cited by 52
Lee, J. H., Lee, Y. S., Jeong, S. A., Khadka, P., Roth, J., & Chung, I. K. (2013) · Histochemistry and Cell Biology · doi:10.1007/s00418-013-1166-x · Cited by 56
Telomere Dysfunction, Chromosomal Instability and Cancer
Meena, J. K., Rudolph, K. L., & Güneş, Ç. (2015) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-20291-4_3 · Cited by 61
Nonhistone targets of KAT2A and KAT2B implicated in cancer biology
Bondy‐Chorney, E., Denoncourt, A. M., Sai, Y., & Downey, M. (2018) · Biochemistry and Cell Biology · doi:10.1139/bcb-2017-0297 · Cited by 51
Slatter, T. L., Hsia, H., Samaranayaka, A., Sykes, P. H., Clow, W. M., Devenish, C. J., Sutton, T., Royds, J. A., Ip, P. P. C., Cheung, A., et al. (2015) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.11 · Cited by 52
“This shortening is circumvented in neoplasia by the activation of telomere maintenance [6].”
BackgroundEid, R., Demattei, M.-V., Episkopou, H., Augé‐Gouillou, C., Decottignies, A., Grandin, N., & Charbonneau, M. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.01317-14 · Cited by 49
Walsh, K. M., Rice, T., Decker, P. A., Kosel, M., Kollmeyer, T. M., Hansen, H. M., Zheng, S. Y., Mccoy, L. S., Bracci, P. M., Anderson, E., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not051 · Cited by 52
Weynand, J., Diman, A., Abraham, M., Marcélis, L., Jamet, H., Decottignies, A., Dejeu, J., Defrancq, É., & Elias, B. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201804771 · Cited by 49
Involvement of Topoisomerase III in Telomere-Telomere Recombination
Tsai, H.-J., Huang, W., Li, T., Tsai, Y.-L., Wu, K., Tseng, S., & Teng, S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600649200 · Cited by 49
Recombination at Long Mutant Telomeres Produces Tiny Single- and Double-Stranded Telomeric Circles
Groff-Vindman, C., Cesare, A. J., Natarajan, S., Griffith, J. D., & McEachern, M. J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.11.4406-4412.2005 · Cited by 50
“Studies have shown that telomeres of ALT cells are both highly heterogeneous in size and frequently much longer than telomeres in normal human cells and telomerase-positive cancer cells (3, 4).”
BackgroundATRX and the replication of structured DNA
Clynes, D., & Gibbons, R. J. (2013) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.01.005 · Cited by 48
Hung, N. A., Eiholzer, R. A., Kirs, S., Zhou, J., Ward‐Hartstonge, K. A., Wiles, A. K., Frampton, C. M., Taha, A. J., Royds, J. A., & Slatter, T. L. (2016) · Modern Pathology · doi:10.1038/modpathol.2015.156 · Cited by 47
Evaluation of Telomere Length Maintenance Mechanisms in Adrenocortical Carcinoma
Else, T., Giordano, T. J., & Hammer, G. D. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1840 · Cited by 47
“of ALT with a very long telomere length (median 19 kb) (18).”
BackgroundResultFalchetti, M. L., Larocca, L. M., & Pallini, R. (2002) · Child s Nervous System · doi:10.1007/s00381-002-0562-7 · Cited by 54
“mented in a subset of tumor-derived cell lines and tumors [3].”
BackgroundTelomerase activity and telomere length in thyroid neoplasia: biological and clinical implications
Matthews, P., Jones, C. J., Skinner, J. W., Haughton, M. F., Micco, C. D., & Wynford‐Thomas, D. (2001) · The Journal of Pathology · doi:10.1002/path.848 · Cited by 52
“Escape from crisis can occur very rarely, leading to an immortal subclone composed of cells which have acquired the ability to maintain their telomeres above the threshold necessary for viable cell division [6], most usually, but not invariably [7], by expression of the ribonuclear protein telomerase.”
BackgroundGastroenteropancreatic endocrine tumors
Weil, C. (1985) · Journal of Molecular Medicine · doi:10.1007/bf01731493 · Cited by 50
Targeting Telomerase and ATRX/DAXX Inducing Tumor Senescence and Apoptosis in the Malignant Glioma
Fan, H., Chen, C., Chi, C.-S., Tsai, J., Chiang, K.-L., Chang, Y., Lin, S., & Harn, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010200 · Cited by 50
“Additionally, Indeed, 5–10% cancer cases exploit a telomerase-independent mechanism to elongate their telomeres, a phenomenon that is also known as ALT [134].”
BackgroundInfluentialHuman Embryonic Stem Cell Stability
Hoffman, L., & Carpenter, M. K. (2005) · Stem Cell Reviews and Reports · doi:10.1385/scr:1:2:139 · Cited by 53
Telomere shortening and the clinicopathologic characteristics of human colorectal carcinomas
Takagi, S., Kinouchi, Y., Hiwatashi, N., Chida, M., Nagashima, F., Takahashi, S., Negoro, K., Shimosegawa, T., & Toyota, T. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991015)86:8<1431::aid-cncr7>3.0.co;2-r · Cited by 47
“some tumor-derived cell lines show telomere elongation without the expression of telomerase activity.(18,19) Furthermore, it has been reported that the telomerase negative, immortal human cells are provided with alternative mechanisms for telomere elongation independent of human telomerase RNA.”
BackgroundPAX8 Regulates Telomerase Reverse Transcriptase and Telomerase RNA Component in Glioma
Chen, Y.-J., Campbell, H. G., Wiles, A. K., Eccles, M. R., Reddel, R. R., Braithwaite, A. W., & Royds, J. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0058 · Cited by 52
Self-citationGu, J. H., Zhang, L., Huang, X., Lin, T.-Y., Yin, M., Xu, K., Ji, L., Roth, J. A., & Fang, B. (2002) · Oncogene · doi:10.1038/sj.onc.1205582 · Cited by 47
“It is noteworthy that Ad/gBax induced weak GFP–Bax expression in some Saos-2 cells, which reportedly use an alternative lengthening of telomeres (ALT) pathway to maintain telomere length rather than using telomerase (Bryan et al., 1997).”
BackgroundWynn, R. F., Thornley, I., Freedman, M. H., & Saunders, E. F. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01450.x · Cited by 50
“Other telomerase-independent means of telomere length preservation are known to exist (Bryan et al, 1997).”
BackgroundTelomerase-directed molecular therapeutics
Keith, W. N., Bilsland, A. E., Evans, T. R. J., & Glasspool, R. M. (2002) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399402004507 · Cited by 57
FEN1 contributes to telomere stability in ALT-positive tumor cells
Saharia, A., & Stewart, S. A. (2009) · Oncogene · doi:10.1038/onc.2008.458 · Cited by 57
Gruhne, B., Kamranvar, S. A., Masucci, M. G., & Sompallae, R. R. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.07.005 · Cited by 49
Life and cancer without telomerase: ALT and other strategies for making sure ends (don’t) meet
Apte, M. S., & Cooper, J. P. (2016) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2016.1260090 · Cited by 47
“The requirements for this strategy have been at least partially defined in a number of ALT cell lines as well as tumors over the past two decades (Bryan et al., 1997; Henson & Reddel, 2010).”
BackgroundThe triggers of the cGAS-STING pathway and the connection with inflammatory and autoimmune diseases
Zhou, R., Xie, X., Li, X., Qin, Z., Wei, C., Liu, J., & Luo, Y. (2019) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2019.104094 · Cited by 46
Epigenetic control of telomerase and modes of telomere maintenance in aging and abnormal systems
Serene, R. L. (2005) · Frontiers in bioscience · doi:10.2741/1661 · Cited by 50
“About 70% of immortalized human somatic cell lines (20) and 90 – 95% of human cancer cells express high levels of telomerase, comparable to cells normally expressing telomerase such as germline cells.”
BackgroundSenescence and immortalization of human cells
Duncan, E. L., Wadhwa, R., & Kaul, S. C. (2000) · Biogerontology · doi:10.1023/a:1010000132671 · Cited by 51
“Several immortal cell lines and primary tumors have no detectable telomerase activity (Murnane et al. 1994; Bryan et al. 1995, 1997).”
BackgroundTelomere Loss in Somatic Cells of Drosophila Causes Cell Cycle Arrest and Apoptosis
Ahmad, K., & Golic, K. G. (1999) · Genetics · doi:10.1093/genetics/151.3.1041 · Cited by 51
Telomere Dynamics in Myelodysplastic Syndromes and Acute Leukemic Transformation
Ohyashiki, K., Iwama, H., Yahata, N., Tauchi, T., Kawakubo, K., Shimamoto, T., & Ohyashiki, J. H. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109064585 · Cited by 46
Non-canonical roles of canonical telomere binding proteins in cancers
Akıncılar, S. C., Chan, C. H. T., Ng, Q. F., Fidan, K., & Tergaonkar, V. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03783-0 · Cited by 47
Killedar, A., Stutz, M. D., Sobinoff, A. P., Tomlinson, C. G., Bryan, T. M., Beesley, J. M., Chenevix‐Trench, G., Reddel, R. R., & Pickett, H. A. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005286 · Cited by 48
“In contrast, in the great majority of cancers and immortalized cell lines telomere length is maintained; in 85% of cancers this is due to upregulated levels of telomerase and in the remainder this is due to a non-telomerase mechanism [8,9].”
BackgroundSelf-citationGuilleret, I., Yan, P., Guillou, L., Braunschweig, R., Coindre, J.-M., & Benhattar, J. (2002) · Carcinogenesis · doi:10.1093/carcin/23.12.2025 · Cited by 49
Gordon, K., Ireland, H., Roberts, M., Steeghs, K., McCaul, J. A., MacDonald, D. G., & Parkinson, E. K. (2003) · PubMed · Cited by 50
Wang, Y., Erdmann, N., Giannone, R. J., Wu, J., Gomez, M., & Liu, Y. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504635102 · Cited by 45
Telomere biology and translational research
Mason, P. J., & Perdigones, N. (2013) · Translational research · doi:10.1016/j.trsl.2013.08.009 · Cited by 45
“involving homologous recombination (19).”
Wang, N., Xu, D., Sofiadis, A., Höög, A., Vukojević, V. B., Bäckdahl, M., Zedenius, J., & Larsson, C. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1158 · Cited by 45
“The ALT mechanism has been described for tumor cells lacking telomerase activation (34), which is common in sarcomas and glioblastoma multiforme.”
BackgroundA genetic strategy to overcome the senescence of primary meningioma cell cultures
Baía, G. S., Slocum, A. L., Hyer, J. D., Misra, A., Sehati, N., VandenBerg, S. R., Feuerstein, B. G., Deen, D. F., McDermott, M. W., & Lal, A. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-9076-y · Cited by 45
“In other cancers, telomere length is maintained by an alternative mechanism for lengthening of telomeres (ALT) [10].”
BackgroundAntitumor effects of telomerase inhibitor TMPyP4 in osteosarcoma cell lines
Fujimori, J., Matsuo, T., Shimose, S., Kubo, T., Ishikawa, M., Yasunaga, Y., & Ochi, M. (2011) · Journal of Orthopaedic Research® · doi:10.1002/jor.21451 · Cited by 44
Lechel, A., Manns, M. P., & Rudolph, K. L. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.06.010 · Cited by 47
“ALT leads to telomere elongation by homologous recombination and copy switching [90–93].”
BackgroundGenes Involved in the Control of Cellular Proliferative Potentiala
Reddel, R. R. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb09887.x · Cited by 44
“In addition, evidence for ALT has recently been found in tumor-derived cell lines and tumors.(10)”
Self-citationTelomerase: biology and phase I trials
Kèlland, L. R. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(00)00226-6 · Cited by 47
Mechanisms of Alternative Lengthening of Telomeres
O’Sullivan, R. J., & Greenberg, R. A. (2024) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041690 · Cited by 59
Genome stability from the perspective of telomere length
Lu, X., & Liu, L. (2023) · Trends in Genetics · doi:10.1016/j.tig.2023.10.013 · Cited by 50
Long telomeres are preferentially extended during recombination-mediated telomere maintenance
Chang, M., Dittmar, J. C., & Rothstein, R. J. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2034 · Cited by 47
“Type II survivors resemble human ALT cells in that both are defined by the presence of long, heterogeneous telomeric repeats8,16,17.”
Telomere length and telomerase activity in malignant lymphomas at diagnosis and relapse
Remes, K., Norrback, K.-F., Rosenquist, R., Mehle, C., Lindh, J., & Roos, G. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.0970 · Cited by 47
“Comparisons of normal and tumour tissues have generally demonstrated shorter telomeres in the tumour samples, but some tumours have demonstrated similar or extended telomere lengths (Hiyama et al, 1995a; Mehle et al, 1996; Norrback and Roos, 1997; Bryan et al, 1997).”
BackgroundSýkorová, E., Lim, K. Y., Fajkus, J., & Leitch, A. R. (2003) · Chromosoma · doi:10.1007/s00412-003-0256-2 · Cited by 43
“Recombination pathways may also serve as backup mechanisms for the maintenance of typical telomeres in telomerasenegative human cancer cells (Bryan et al. 1997).”
BackgroundIs hEXO1 a Cancer Predisposing Gene?
Liberti, S. E., & Rasmussen, L. J. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.427.2.8 · Cited by 49
“Such alternative mechanisms are detectable in a small percentage of tumors, including bone and soft tissue sarcomas, glioblastomas, and carcinomas of the lung, kidney, breast, and ovary (57-60).”
BackgroundLundberg, G., Sehic, D., Länsberg, J., Øra, I., Frigyesi, A., Castel, V., Navarro, S., Piqueras, M., Martinsson, T., Noguera, R., et al. (2011) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20850 · Cited by 47
“Telomere stabilization can be achieved by human cancer cells by de novo synthesis of telomeric DNA by telomerase or by ALT, which is dependent on recombination of telomeres in PML-bodies (Bryan et al., 1997; Draskovic et al., 2009).”
Fleisig, H. B., Hukezalie, K. R., Thompson, C. A. H., Au‐Yeung, T., Ludlow, A. T., Zhao, C., & Wong, J. M. Y. (2015) · Oncogene · doi:10.1038/onc.2015.75 · Cited by 43
TERRA, hnRNP A1, and DNA-PKcs Interactions at Human Telomeres
Le, P. N., Maranon, D. G., Altina, N. H., Battaglia, C. L. R., & Bailey, S. M. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00091 · Cited by 45
“Those tumors that do not express telomerase maintain telomere length via a recombination-based mechanism termed alternative lengthening of telomeres (ALT) (Murnane et al., 1994; Bryan et al., 1997; Dunham et al., 2000).”
Rapid and reversible suppression of ALT by DAXX in osteosarcoma cells
Yost, K. E., Soper, S. F. C., Walker, R. L., Pineda, M. A., Zhu, Y. J., Ester, C. D., Showman, S., Roschke, A. V., Waterfall, J. J., & Meltzer, P. S. (2019) · Scientific Reports · doi:10.1038/s41598-019-41058-8 · Cited by 45
Farooqi, A. S., Dagg, R. A., Choi, L. M. R., Shay, J. W., Reynolds, C. P., & Lau, L. M. S. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1456-8 · Cited by 43
“In contrast, ALT is a telomerase-independent mechanism where telomeric DNA is replicated via homologous recombination using DNA as template [8–10] and is much more prevalent in tumors of mesenchymal and neuroepithelial origin [11].”
MethodJiang, W.-Q., Nguyen, A., Cao, Y., Chang, A. C.-M., & Reddel, R. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017036 · Cited by 45
“[1,2], and is utilized by many types of tumors including sarcomas”
BackgroundSelf-citationhTERT gene dosage correlates with telomerase activity in human lung cancer cell lines
Saretzki, G. C., Petersen, S., Petersen, I., Kölble, K., & von Zglinicki, T. (2002) · Cancer Letters · doi:10.1016/s0304-3835(01)00644-9 · Cited by 50
Sotillo, E., Sierrasesúmaga, L., & Patiño‐García, A. (2003) · Pediatric Research · doi:10.1203/01.pdr.0000102455.36737.3c · Cited by 46
“However, it could also indicate that ALT mechanisms generate longer telomeres than telomerase.”
BackgroundInfluentialAlternative lengthening of telomeres: dangerous road less travelled
Reddel, R. R., & Bryan, T. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13538-6 · Cited by 42
Self-citationVilla, R., Porta, C. D., Folini, M., Daidone, M. G., & Zaffaroni, N. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2001.01343.x · Cited by 45
hTERT promotes the invasion of telomerase-negative tumor cells in vitro
Yang, Y. (2009) · International Journal of Oncology · doi:10.3892/ijo_00000344 · Cited by 45
“It was widely believed for many years that telomerase was the only telomere lengthening mechanism involved in cell aging and tumorigenesis, until the unveiling of the alternative lengthening of telomere (ALT) mechanism (10,11), which is characterized by instability at a specific minisatellite locus and high rates of t…”
BackgroundRowland, T. J., Dumbović, G., Hass, E. P., Rinn, J. L., & Cech, T. R. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908275116 · Cited by 47
“We also included induced pluripotent stem cells (iPSCs) (line WTC-11), which express TERT, and an osteosarcoma cancer cell line (U-2 OS) known to use the alternative lengthening of telomeres (ALT) mechanism and therefore be telomerase-negative (28).”
BackgroundRowland, T. J., Bonham, A. J., & Cech, T. R. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12786 · Cited by 45
Subcellular distribution of nuclear import-defective isoforms of the promyelocytic leukemia protein
Jul‐Larsen, Å., Grudic, A., Bjerkvig, R., & Bøe, S. O. (2010) · BMC Molecular Biology · doi:10.1186/1471-2199-11-89 · Cited by 43
“Interestingly, both cell lines (U2OS and GM847) that were found to support targeting of PML to the nuclear periphery are ALT cells, cells that use alternative lengthening of telomeres (ALT) and not telomerase as their primary mechanism for telomere elongation [35,36].”
BackgroundSuzuki, T., Yokozaki, H., Kuniyasu, H., Hayashi, K., Naka, K., Ono, S., Ishikawa, T., Tahara, E., & Yasui, W. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001215)88:6<992::aid-ijc24>3.0.co;2-9 · Cited by 121
Wan, M. S., Fell, P. L., & Akhtar, S. (1998) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1998.8.309 · Cited by 43
“There may also be alternative (ALT) pathways for maintaining telomere length, as has been suggested recently (Bryan et al., 1997).”
Progressive lung fibrosis: reprogramming a genetically vulnerable bronchoalveolar epithelium
Bridges, J. P., Vladar, E. K., Kurche, J. S., Krivoi, A., Stancil, I. T., Dobrinskikh, E., Hu, Y., Sasse, S. K., Lee, J. S., Blumhagen, R. Z., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci183836 · Cited by 46
“Continued replication after telomere attrition requires telomere lengthening to prevent chromatin erosion (144, 162, 163).”
Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis
Venturini, L., Motta, R., Gronchi, A., Daidone, M. G., & Zaffaroni, N. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-254 · Cited by 40
“Among these, 6 and 8 lesions were defined as ALT+/TA+ based on the expression of APB or on TRF length distribution, respectively, thus confirming the possibility that the two TMM coexist in the same lesion as previously reported also for other tumor types [3,17,18].”
Verver, D. E., van Pelt, A. M. M., Repping, S., & Hamer, G. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.269 · Cited by 48
“Although DNA damage repair has long been proposed to be its main function, in many mammalian cancer cells lacking telomerase activity, Smc5/6 is also involved in a process called alternative lengthening of telomeres (ALT) by promoting intra-telomeric recombination [14, 18-20].”
BackgroundFogli, A., Demattei, M.-V., Corset, L., Vaurs‐Barrière, C., Chautard, E., Biau, J., Kémény, J., Godfraind, C., Pereira, B., Khallil, T., et al. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2585-7 · Cited by 40
“However, some cancer cells maintain their telomeres through a telomerase-independent process termed ALT, for “alternative lengthening of telomeres” [2].”
BackgroundDey, A., & Chakrabarti, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020333 · Cited by 47
“A better understanding of this ALT based pathway is now necessary to develop new strategies for combating cancer.”
BackgroundInfluentialThe many facets of homologous recombination at telomeres
Claussin, C., & Chang, M. (2015) · Microbial Cell · doi:10.15698/mic2015.09.224 · Cited by 43
“The remaining 10–15% of cancers employ telomerase-independent, recombination-based mechanisms, collectively termed alternative lengthening of telomeres (ALT) [10].”
BackgroundLoss of Telomere Protection: Consequences and Opportunities
Jacobs, J. J. L. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00088 · Cited by 49
“Most tumors activate telomerase while 10–15% of tumors activate ALT www.frontiersin.org April 2013 | Volume 3 | Article 88 | 3 (Bryan et al., 1997; Shay and Bacchetti, 1997).”
Association of BLM and BRCA1 during Telomere Maintenance in ALT Cells
Acharya, S. K., Kaul, Z., Gocha, A. R. S., Martinez, A. R., Harris, J. M., Parvin, J. D., & Groden, J. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103819 · Cited by 51
Telomere-independent ageing in the longest-lived non-colonial animal, Arctica islandica
Gruber, H., Schaible, R., Ridgway, I. D., Chow, T. T., Held, C., & Philipp, E. E. R. (2014) · Experimental Gerontology · doi:10.1016/j.exger.2013.12.014 · Cited by 42
“The activation of the enzyme telomerase (Aubert and Lansdorp, 2008) or alternative telomere lengthening pathways (Bryan et al., 1997) can maintain telomere lengths, leading to theoretically unlimited proliferative potential.”
Braunstein, I., Cohen‐Barak, O., Shachaf, C. M., Ravel, Y., Yalon-Hacohen, M., Mills, G. B., Tzukerman, M., & Skorecki, K. L. (2001) · PubMed · Cited by 46
Metadata
- Authors
- Bryan, T. M., Englezou, A., Dalla-Pozza, L., Dunham, M. A., & Reddel, R. R.
- Affiliations
- Children's Medical Research Institute (AU)
- Corresponding author
- Reddel, Roger R.
- Venue
- Nature Medicine
- Published
- 1997-11
- Volume
- 3
- Issue
- 11
- Pages
- 1271-1274
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2013073993
- Cited by
- 1,292
- References
- 39
- Citations by year
- 2026: 19 · 2025: 41 · 2024: 37 · 2023: 48 · 2022: 31 · 2021: 34 · 2020: 44 · 2019: 52 · 2018: 27 · 2017: 54 · 2016: 35 · 2015: 52 · 2014: 33 · 2013: 52 · 2012: 39
- FWCI
- 27.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
- Keywords
- alternative lengthening of telomeres, telomere maintenance, telomerase, tumor-derived cell lines, cell immortalization, telomerase inhibitors, cancer therapy, telomere loss
- MeSH terms
- Adult, DNA Nucleotidyltransferases, Humans, Neoplasms, Tumor Cells, Cultured, Deoxyribonucleases, Type II Site-Specific, Telomere, Telomerase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.